Small molecule inhibitors and monoclonal antibodies that target relevant cancer-related proteins have enabled successful treatments for blood cancers (e.g., imatinib for CML) and some solid tumors (e.g., trastuzumab for HER2-positive breast cancer and tamoxifen for ER-positive breast cancer). Here, ERBB2 is linked to breast carcinoma.